Projects per year
Personal profile
Education
- 2016 臺北醫學大學藥學系博士班博士
- 2011 臺北醫學大學藥學系碩士班碩士
- 2009 臺北醫學大學藥學系學士
Experience
- 2023- 臺北醫學大學藥物科學學科副教授
- 2022-2023 臺北醫學大學新藥開發研究中心副研究員
- 2021-2022 臺北醫學大學新藥開發研究中心助理研究員
- 2018-2021 臺北醫學大學生技醫藥商品中心助理研究員
- 2016-2018 臺北醫學大學博士後研究員
Fingerprint
Dive into the research topics where Yi-Min Liu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
合成系列醯基苯甲酸衍生物作為鈣離子通道阻斷劑小分子用於頭頸癌的治療
Liu, Y.-M. (PI)
8/1/24 → 7/31/25
Project: A - Government Institution › b - National Science and Technology Council
-
具抗癌效果之鈣離子釋放激活鈣離子通道抑制劑：利用有機金屬耦合反應合成嘧啶苯甲醯胺類為骨架之系列衍生物
Liu, Y.-M. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
設計及合成 LSD1/HDAC抑制劑作為抗大腸直腸癌劑
Liu, Y.-M. (PI)
1/1/22 → 12/31/22
Project: B - Project of TMU › h - Higher Education Sprout Project
-
Selective Hdac Inhibitor with Anti-Fibrosis Effect: Pyridone as Core Structure via the Use of Organometallic Coupling Reaction in the Synthesis of Series Derivatives
Liu, Y.-M. (PI)
8/1/21 → 7/31/22
Project: A - Government Institution › b - National Science and Technology Council
-
標的蛋白降解技術: 含氮三環化合物為骨架利用有機金屬耦合反應合成系列衍生物
Liu, Y.-M. (PI)
8/1/20 → 7/1/21
Project: A - Government Institution › b - National Science and Technology Council
-
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020–present)
Liu, Y. M. & Liou, J. P., 2023, (Accepted/In press) In: Expert Opinion on Therapeutic Patents. 33, 5, p. 349-369 21 p.Research output: Contribution to journal › Review article › peer-review
15 Citations (Scopus) -
Enantioselective Intramolecular Hydroacylation of Alkynes by Rhodium Catalysis through Dynamic Kinetic Resolution
Oonishi, Y., Takagishi, K., Liu, Y. M. & Sato, Y., Oct 24 2023, In: Advanced Synthesis and Catalysis. 365, 20, p. 3432-3437 6 p.Research output: Contribution to journal › Article › peer-review
-
Erratum: N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling (J. Med. Chem. (2015) 58:16 (6549−6558) DOI: 10.1021/acs.jmedchem.5b00659)
Lai, M. J., Lee, H. Y., Chuang, H. Y., Chang, L. H., Tsai, A. C., Chen, M. C., Huang, H. L., Wu, Y. W., Teng, C. M., Pan, S. L., Liu, Y. M., Mehndiratta, S. & Liou, J. P., May 11 2023, In: Journal of Medicinal Chemistry. 66, 9, p. 6436 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Citation (Scopus) -
2,6-Difluorobenzamide derivatives as store-operated calcium channel (SOC) inhibitors
Wang, Y. S., Yeh, T. K., Chang, W. C., Liou, J. P., Liu, Y. M. & Huang, W. C., Dec 5 2022, In: European Journal of Medicinal Chemistry. 243, 114773.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis: Erratum
Huang, H. L., Liu, Y. M., Sung, T. Y., Huang, T. C., Cheng, Y. W., Liou, J. P. & Pan, S. L., Jan 1 2021, In: Theranostics. 11, 5, p. 2079 1 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus)